

Characterization of Canine Triiodothyronine (T₃) Autoantibodies and Their Effect on Total T₃ in Canine Serum (42731)

DIANE W. YOUNG, ROBERT J. KEMPPAINEN, AND JAMES L. SARTIN

Department of Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Alabama 36849

Abstract. A study of 3,5,3'-L-triiodothyronine autoantibody (T₃ AA) in 18 dogs revealed an average apparent affinity constant for T₃ of $2.24 \pm 1.78 \times 10^{10} M^{-1}$, an average T₃ binding capacity of 639.3 ± 666.5 ng/dl and a low thyroxine (T₄) cross-reactivity (<1%) in all samples tested. A valid radioimmunoassay (RIA) procedure which involved heat treatment of samples for 1 hr at 70°C and assay on Sephadex minicolumns was developed for measuring T₃ in the presence of T₃ AA. Total T₃ was elevated ($\bar{x} = 374.8 \pm 158.4$ ng/dl) in samples in which T₄ was in the normal canine range, but T₃ was lower ($\bar{x} = 96.1 \pm 63.3$ ng/dl) in samples with T₄ values in the hypothyroid range. For each sample the concentration of T₃ not bound by T₃ AA was calculated from the total T₃ concentration, the affinity constant, and the binding capacity. In dogs with normal total T₄ concentrations the average calculated T₃ not bound by T₃ AA was 147.2 ± 144.4 ng/dl while in dogs with low total T₄ the value was 15.7 ± 26.3 ng/dl (normal canine range is 45–150 ng/dl). Canine samples containing T₃ AA were compared to serum from three rabbits actively immunized against T₃ to provide anti-T₃ for commercial RIA. The rabbit T₃-antisera had an average T₃ affinity constant similar to those of the canine samples ($1.57 \times 10^{10} M^{-1}$), but had average titer, T₃ binding capacity, and total T₃ values more than 10-fold higher. Our findings indicate that, in dogs with serum containing T₃ AA and normal total T₄ concentrations, a compensatory mechanism appears to exist to maintain non-T₃ AA bound T₃ within the range of normal total T₃. This compensatory mechanism does not operate in those dogs with insufficient thyroid activity to maintain normal total T₄ values. © 1988 Society for Experimental Biology and Medicine.

Autoimmune phenomena appear to be involved in many aspects of thyroid disease. Hyperthyroidism in Graves disease, due to thyroid stimulating autoantibodies specific to the TSH receptor, and hypothyroidism due to autoimmune destructive thyroiditis with associated antithyroid autoantibodies are examples (1). Autoimmune phenomena have also been reported in the dog where autoantibodies to thyroglobulin were found in 59% of hypothyroid dogs and autoantibodies to thyroid microsomes in 29% (2).

Spontaneous thyroid hormone autoantibodies have been reported in human patients, both clinically euthyroid (3–5) and hypothyroid (5, 6). These individuals are singled out since thyroid hormone autoantibodies interfere with RIA procedures for thyroid hormone measurement resulting in dramatically elevated apparent values using solid phase RIA methods (3) or lowered apparent values using charcoal separation methods (5). Interference in double antibody procedures depends on whether the labeled hormone bound to the autoantibody is pre-

cipitated in the RIA procedure (4). Elevated total T₃ levels have been reported in human patients with T₃ autoantibody (T₃ AA) (3, 5) and in rabbits (7) and rats (5) immunized against T₃ or T₄. In an attempt to determine whether total T₃ was elevated in canine samples containing T₃ AA, an RIA method was developed which accurately measured T₃ in these samples. Various authors, who have reported measuring T₃ in the presence of T₃ AA, either extracted serum or plasma samples in ethanol (3, 5), assayed samples in the presence of cold T₄ to saturate the autoantibody (8), or used an RIA involving Sephadex minicolumns (2, 9).

Abnormal canine T₃ binding factors were shown in a previous report to exhibit a high apparent affinity constant for T₃, a relatively high heat stability compared with that of human thyroxine binding globulin (TBG), a lack of inhibition of binding to T₃ by 8-anilino-1-naphthalene sulfonic acid (ANS), and precipitability by goat anti-canine IgG (10). The purpose of the present study was to provide additional evidence that these T₃ bind-

ing factors are autoantibodies, to characterize T₃ AA in more detail, and to develop a procedure to accurately measure total T₃ in the presence of T₃ AA.

Materials and Methods. Samples. Canine serum samples (controls and samples containing T₃ AA) were obtained as samples submitted by veterinarians to the Endocrine Diagnostic Service of Auburn University, College of Veterinary Medicine for thyroid hormone analysis. Total T₃ and total T₄ measurements were requested for evaluation of the thyroid status of pet dogs. Samples yielding extremely high apparent total T₃ values, or inappropriately high total T₃ relative to total T₄, were screened for the presence of T₃ AA by determining the capacity of the serum to bind [¹²⁵I]T₃. Samples used in this study were taken from dogs which had not received thyroid medication.

Basic binding assay. Triiodothyronine binding was determined under a variety of conditions by variations on the basic binding assay. Samples (usually 100 μ l) were incubated with 0.5 ml phosphate-buffered saline (PBS), pH 7.4, containing 0.1% gelatin (gel PBS), 100 μ l [¹²⁵I]T₃ (Clinical Assays; Cambridge, MS) containing 0.025 μ Ci and 100 μ l unlabeled thyroid hormone solution (where appropriate) at 37°C for 1 hr, then at 5°C for 2 hr. Bound and free fractions were separated by adding 0.5 ml of 1.25% dextran-coated charcoal in PBS (DCC), incubating at 5°C for 10 min, then centrifuging at 2000g for 10 min. The supernatant (bound fraction) was decanted and radioactivity determined using a 4/200 Automatic Gamma Counter (Micromedic Systems; Horsham, PA). Under these conditions undiluted sera from dogs without T₃ AA bound less than 10% of [¹²⁵I]T₃.

Second antibody precipitability. Canine sera were diluted to bind approximately 50% of [¹²⁵I]T₃ when 25 μ l of diluted serum was assayed in the basic binding assay (total T₃ binding). In addition 25 μ l of a series of 1:2 dilutions of three different "second antibodies" [goat anti-canine IgG (Cooper Biomedical; Malvern, PA), goat anti-canine IgM, and anti-canine IgA (Pel-Freeze Biologicals; Rogers, AR)] was added and the tubes incubated for 48 hr at 5°C. After the addition of 2 ml of saline containing polyethylene glycol

the tubes were centrifuged at 2000g for 20 min. The supernatants were decanted and the pellets, representing precipitable T₃ binding, were counted.

Electrophoresis. Duplicate serum samples suspected of containing T₃ autoantibodies were applied to 2.5 $\times$ 15 cm Sepharose III cellulose polyacetate strips (Gelman Instrument Co; Ann Arbor, MI) and electrophoresed for 1 hr at 250 V in Tris barbital high resolution buffer, pH 8.6 (Helena Laboratories, Beaumont, TX), in a Deluxe electrophoresis chamber with regulated power supply (Gelman Instrument Co). One lane was stained in amino black and scanned with a Quick Scan Jr. densitometer (Helena Laboratories). The remaining lane was cut into 32-mm fractions and each fraction eluted in 0.7 ml gel PBS by shaking for 30 min. Each eluted fraction was assayed for T₃ binding using the basic binding assay.

Routine T₄ and T₃ RIA. Total T₄ was measured in canine serum samples with a double antibody Canine T₄ RIA kit procedure (Diagnostic Products Corp; Los Angeles, CA) validated for use in the dog (11). Apparent total T₃ was measured using the Diagnostic Products solid phase Canine T₃ method validated for canine samples (unpublished data).

T₃ affinity constant and T₄ cross-reactivity determination. Apparent T₃ affinity constants were determined as described in a previous report (10). Sera diluted to bind 50% of [¹²⁵I]T₃ in the basic binding assay were incubated in the presence of [¹²⁵I]T₃ and unlabeled T₃ at seven concentrations from 0 to 100 ng/dl. Scatchard analysis (12) of the resulting data was performed to determine the affinity constant and binding capacity in each sample.

T₄ cross-reactivity was determined using the ED₅₀ in similar experiments except that [¹²⁵I]T₃ binding was measured in the presence of five concentrations of nonradioactive T₄ (0 to 1250 ng/ml) and 5 mM ANS to prevent binding of T₄ to TBG.

Autoantibody titer determination. Serial 1:2 dilutions of serum were carried out in gel PBS and the percentage binding was determined in the basic binding assay. Titer, the dilution factor that results in exactly 50% binding, was extrapolated from the data.

Ethanol extraction. Ethanol extraction of canine samples was performed at various ratios of ethanol/serum in an attempt to remove or inactivate T₃ AA and allow accurate RIA for total T₃. The effect of ethanol extraction on T₃ binding activity, and apparent total T₃ using the routine solid phase RIA, was determined in samples containing T₃ AA and in sera from normal dogs.

Radioimmunoassay of T₃ in the presence of T₃ autoantibody. RIA of total T₃ in the presence of T₃ AA was based on a modification of the method of Alexander and Jennings (9). Serum samples and T₃ standards prepared in charcoal stripped canine serum were diluted 3:5 in 100 µg/ml thermolysin protease (Sigma Chemical Co.; St. Louis, MO) in distilled water and heated at 70°C for 1 hr. Heat treated samples and standards were diluted 2:3 with [¹²⁵I]T₃ (0.025 µCi/100 µl) solution in 80 mM NaOH, and 0.3 ml of this solution was added in duplicate to small columns containing 1.5 ml of Sephadex G25-50 (Pharmacia, Uppsala, Sweden) equilibrated in 80 mM NaOH. After samples had penetrated the gel, the columns were washed with 2.0 ml of 75 mM sodium barbital buffer (pH 8.6) to remove proteins (including T₃ AA). T₃ antiserum (Wien Laboratories, Inc; Succasuma, NJ), diluted to result in 50% binding in the 0 standard columns, was added (0.5 ml) and allowed to incubate for 1 hr at room temperature. The antibody bound fraction was then eluted with 1.5 ml barbital buffer, and the radioactivity measured using a gamma counter. Total T₃ was calculated using a log-logit transformation. The columns were regenerated by rinsing with 4 ml of charcoal stripped canine sera diluted 1:20 in distilled water.

Results. A major portion of the abnormal T₃ binding activity in serum from five dogs was precipitable by goat anti-canine IgG, but was not precipitable with goat anti-canine IgA or goat anti-canine IgM (Table I). Additionally, the T₃ binding activity in these dogs was found to migrate with the β- and γ-globulin fractions on electrophoresis (Fig 1). In 2 of the dogs a fast migrating peak of T₃ binding activity was observed, but we were unable to determine the nature of this material.

A study of serum from 18 dogs with T₃ AA was performed to investigate the nature of

TABLE I. SECOND ANTIBODY PRECIPITABLE [¹²⁵I] T₃ AS PERCENTAGE OF TOTAL [¹²⁵I] T₃ BOUND IN CANINE SERUM CONTAINING T₃ AA

Dog	Anti-canine IgG	Anti-canine IgA	Anti-canine IgM
1	69.6	0.4	0
2	92.3	0.3	0
3	116.0	0	0
4	65.8	0.1	0
5	84.8	0	0.5

the T₃ binding and its possible effect on thyroid physiology. Results of this study are presented in Table II. T₄ levels were clearly in the hypothyroid range in 11 out of 18 of the dogs. The normal range for canine serum samples is 45–150 ng/dl for the routine total T₃ RIA and 1.5–4.0 µg/dl for total T₄ RIA. T₄ binding in the presence of 5 mM ANS (data not shown) was above normal in only one of the samples and there was no indication of interference in the T₄ RIA in any sample. Apparent total T₃ values as measured with the routine solid phase RIA were spuriously elevated and ranged from values which were only slightly above normal to values greater than 5000 ng/dl. T₃ AA titer ranged from 17.6 to 1,223.0 ($\bar{x}$ = 357.0). The T₃ apparent affinity constant averaged $2.24 \times 10^{10} M^{-1}$ indicating a high affinity for T₃. Cross-reactivity with T₄ was <1% in all 18 samples examined.

Efforts to accurately measure total T₃ in canine samples containing T₃ AA by extracting in ethanol were not successful. Ethanol extraction, while efficiently extracting [¹²⁵I]T₃, resulted in less efficient and highly variable results when comparing assayed values of total T₃ in canine samples without T₃ AA before and after extraction. Hehrmann *et al.* (5) using extraction in 1 vol 95% ethanol measured total T₃ in serum from rats immunized to T₃. In canine samples containing T₃ AA extracted in an identical manner, the binding of [¹²⁵I]T₃ was reduced to 40% of the initial value. This level of binding would cause falsely elevated values using the routine total T₃ RIA.

Although heat treatment of T₃ AA at 60°C was totally ineffective in altering binding activity, treatment of samples from five dogs




FIG. 1. Electrophoresis pattern of serum from five dogs with T₃ AA.

(diluted to bind 50% of [¹²⁵I]T₃ in the basic binding assay) at 70°C for 1 hr essentially eliminated T₃ AA binding (Fig. 2). Heat inactivation of samples followed by RIA for total T₃ using the routine solid phase RIA proved impractical since the heat treatment itself in canine samples not containing T₃ AA interfered with the assay resulting in elevated values (Table III).

The Sephadex total T₃ RIA method (9), designed to remove interfering proteins after release of T₃ at alkaline pH, in combination with treatment of samples diluted in thermolysin at 70°C for 1 hr, was validated for measurement of total T₃ in canine samples containing T₃ AA. Sample dilution was minimized due to limitations of assay sensitivity, and temperature of treatment was mini-

TABLE II. THYROID HORMONE CONCENTRATIONS AND THYROID HORMONE BINDING CHARACTERISTICS OF SERUM FROM DOGS WITH T₃ AA

Dog	Total T ₄ (μg/dl)	Apparent T ₃ ^a (ng/dl)	Total T ₃ ^b (ng/dl)	T ₃ AA titer	T ₃ Affinity constant (×10 ¹⁰ M ⁻¹)	Binding capacity (ng/dl)	Non-T ₃ AA bound (T ₃ ng/dl)
Normal T ₄							
1	1.6	1039.6	353.0	808.4	5.79	284.7	71.2
2	1.6	272.5	185.2	148.1	0.63	334.3	11.6
3	1.9	205.1	566.8	74.3	3.98	82.8	424.3
4	1.9	415.3	568.7	256.0	1.88	388.5	192.5
5	1.8	231.9	449.4	65.3	0.99	321.7	142.3
6	2.2	584.6	211.3	49.2	0.31	1560.0	3.4
7	2.0	509.4	289.1	61.9	4.12	104.5	185.2
$\bar{x} \pm SD$	1.86 ± 0.215	465.5 ± 290.9	374.8 ± 158.4	209.0 ± 274.2	2.53 ± 2.11	396.3 ± 507.7	147.2 ± 144.4
Low T ₄							
A	0.6	>600 ^c	52.4	1223.0	1.87	2376.9	0.072
B	0.3	6158.0	104.2	>1000 ^c	1.75	1352.7	0.326
C	0.3	891.0	54.0	412.4	0.55	1530.4	0.451
D	0.3	2646.5	85.2	948.8	6.18	714.8	0.250
E	0.3	1666.5	176.3	431.1	1.09	1096.7	1.17
F	0.7	1368.4	229.6	475.1	3.39	163.3	70.7
G	0.5	152.0	97.2	17.6	1.54	47.3	53.5
H	0.8	427.3	46.7	82.3	2.61	379.6	0.36
I	0.2	199.0	—	148.4	1.65	209.4	—
J	0.3	617.3	93.3	191.3	0.20	504.8	28.6
K	0.2	226.1	22.2	32.0	1.87	55.3	2.03
$\bar{x} \pm SD$	0.41 ± 0.21	1359.3 ± 1763.0	96.1 ± 63.3	451.1 ± 425.0	2.06 ± 1.62	766.5 ± 744.8	15.7 ± 26.3

^a Routine solid phase RIA.^b Modified Sephadex RIA.^c For statistical purposes, these values were taken as exact.

mized to prevent coagulation of samples. Thermolysin (100 μg/ml) did not enhance inactivation of T₃ AA during the heat treatment, but did prevent coagulation of samples. The modified Sephadex total T₃ method was less sensitive to the 70°C heat treatment and to the presence of thermolysin than the solid phase RIA (Table III).

Elevated T₃ binding, which could cause interference in the modified Sephadex method, would appear as increased [¹²⁵I]T₃ in the initial 2 ml rinse prior to incubation with antibody and in the 1.5 ml rinse after incubation. The results shown in Table IV indicate that the 70°C heat treatment eliminates both indications of elevated nonspecific binding when canine samples containing T₃ AA are assayed for total T₃.

Triiodothyronine added to canine serum containing T₃ AA was recovered with greater efficiency in 70°C heat treated samples by the Sephadex method than with the standard solid phase RIA (Table V). Serum containing

T₃ AA was diluted in charcoal stripped canine serum and the samples were analyzed by the modified Sephadex method. The standard and sample inhibition curves are depicted in Fig. 3. Recoveries of T₃ at dilutions of 1:2, 1:3, and 1:4 were 88.5%, 129.9%, and 98.7%, respectively.

In order to substantiate that the modified Sephadex RIA method provided accurate results, samples from normal and hypothyroid dogs (not containing T₃ AA) and from hyperthyroid cats (a source of endogenously elevated T₃) were assayed using both the solid phase and Sephadex methods (Fig. 4). There was good correlation between the assay methods in samples not containing T₃ AA.

Analysis of sera from 18 dogs with T₃ AA indicated no significant difference ($P > 0.1$) in apparent total T₃ (solid phase RIA), autoantibody titer, T₄ cross-reactivity, and binding capacity between dogs with normal total T₄ values and those with low total T₄ (Table II). The total T₃ determined by the

TABLE III. EFFECT OF 70°C HEAT TREATMENT IN THE PRESENCE AND ABSENCE OF THERMOLYSIN ON ASSAYED TOTAL T₃ VALUES IN A CANINE SERUM POOL NOT CONTAINING T₃ AUTOANTIBODY

	TL	70°C treatment	Modified Sephadex RIA		Solid phase RIA	
			Corrected total T ₃ ng/dl	% recovery	Corrected total T ₃ ng/dl	% recovery
Control I	—	—	202.8	95.3	122.0	67.7
Control II	—	+	226.4	106.3	143.0	79.4
Control III	+	—	231.2	108.5	107.8	59.8
Treatment	+	+	188.2	88.4	267.6	148.5
Undiluted pool	—	—	212.9	—	180.2	—

modified Sephadex method and the calculated total T₃ not bound by T₃ AA were significantly higher in the dogs with normal T₄ levels ($P < 0.001$ and $P < 0.05$, respectively).

In addition, samples from three rabbits actively immunized to T₃ (Wein Laboratories; Succasunna, NJ) were assayed by the Sephadex method. Rabbit samples diluted 1:1000 were analyzed for T₃ binding and total T₃ (Table VI). T₃ antibody in the rabbit antisera

was not inactivated by heating at 70°C for 1 hr, but was inactivated by a 10-min treatment at 100°C, therefore rabbit samples were given the latter treatment prior to RIA. Although the modified Sephadex method has not been validated for use in anti-T₃ rabbit sera, values obtained for total T₃ (using heat treatment at 100°C) were in agreement with those of Nieschlag *et al.* (7). In the rabbit samples, total T₃ levels were profoundly elevated ($63,013 \pm 102,703$ ng/dl). The T₃ AA titer was much higher ($40,363 \pm 29,136$) than in spontaneous canine T₃ AA samples (357.0 ± 384.1) while the average T₃ affinity constant ($1.57 \pm .42 \times 10^{10} \text{ M}^{-1}$) was lower than in the canine samples which contained T₃ AA.

Since a large volume of serum was available from a dog with T₃ AA of high T₃ affin-




FIG. 2. Effect of heat treatment on inactivation of T₃ AA in serum from five dogs.

TABLE IV. EFFECT OF 70°C HEAT TREATMENT IN THE PRESENCE OF THERMOLYSIN ON NONSPECIFIC BINDING IN THE MODIFIED SEPHADEX RIA USING CANINE SAMPLES WITH AND WITHOUT T₃ AA

Treatment	Sample	cpm as % of total count	
		2.0 ml rinse prior to antibody addition	1.5 ml rinse after antibody addition
Control	0 standard	4.0	0.2
	Canine serum ^a	5.1	0.4
	T ₃ AA sample	21.4	1.5
70°C	0 standard	4.3	0.2
	Canine serum ^a	4.4	0.9
	T ₃ AA sample	4.8	0.6

^a Values are mean of four canine samples not containing T₃ AA.

TABLE V. TOTAL T₃ ASSAYED VALUES AND PERCENTAGE RECOVERY OF ADDED T₃ IN A CANINE SERUM SAMPLE CONTAINING T₃ AA HEAT TREATED AT 70°C FOR 1 hr IN THE PRESENCE OF THERMOLYSIN

T ₃ added (ng/dl)	Modified sephadex RIA		Solid phase RIA		
	T ₃ observed (ng/dl)	% recovery	T ₃ observed (ng/dl)	% recovery	T ₃ observed (ng/dl) control ^a
0	34.0	—	31.7	31.7	1022.6
25	51.8	87.8	38.8	68.4	1483.3
50	90.3	107.5	42.8	52.4	1363.8
100	113.2	84.5	48.2	36.6	1466.7
200	179.3	76.6	58.2	28.1	1527.2
400	361.9	83.4	134.7	28.7	1474.0
800	724.4	86.9	238.5	28.7	1304.9

^a Not heat treated.

ity (dog D, Table II), a high sensitivity T₃ RIA using canine serum containing T₃ AA as the source of antibody was designed. This RIA utilizing "spontaneous anti-T₃ antibody" and based on the basic binding assay had a sensitivity of 0.08 ng/dl (based on the apparent T₃ concentration at 2 standard deviations below the 0 bound count), and an ED₅₀ of 1.71 ng/dl. This T₃ RIA was more than 10 times as sensitive as most conventional T₃ RIA procedures.

In dogs with T₃ AA there was a clear correlation between the total T₄ value and clinical signs reported. Dogs with total T₄ values

in the normal range exhibited few symptoms typical of hypothyroidism (13), while dogs with low total T₄ values all exhibited one or more of these symptoms (Table VII). Due to limited access to the dogs we were able to confirm hypothyroidism by TSH response test (14) in only two of the dogs (dogs D and E, Table II).

Discussion. Abnormal T₃ binding factors in canine serum samples submitted for routine clinical thyroid hormone analysis have




FIG. 3. Inhibition curves for standards and dilutions of a sample containing T₃ AA using the modified Sephadex total T₃ RIA.




FIG. 4. Total T₃ concentration in samples assayed by a solid phase T₃ RIA and the modified Sephadex RIA. (Canine samples, not containing T₃ AA—closed circles; feline samples—open circles).

TABLE VI. CHARACTERISTICS OF T₃ ANTISERUM FROM THREE RABBITS IMMUNIZED TO T₃

Rabbit	Titer	T ₃ binding capacity (ng/dl)	T ₃ affinity constant ($\times 10^{10} M^{-1}$)	Total T ₃ (ng/dl)
1	73,720	627,500	1.20	181,600
2	27,480	64,000	2.03	46,600
3	19,890	141,800	1.48	27,900
$\bar{x} \pm SD$	40,363 $\pm 29,136$	277,767 305,366	1.57 ± 0.42	85,333 $\pm 83,886$

been identified as T₃ autoantibody (T₃ AA). Autoantibody in these samples was precipitable by goat anti-canine immunoglobulin G (IgG) and co-migrated with canine IgG during electrophoresis. T₃ AA appears to be present in approximately 0.2% of canine serum samples submitted for thyroid hormone analysis (10). Interestingly, T₃ AA occurred in the same frequency in a human clinical endocrinology laboratory (5). The occurrence of T₃ AA, unlike autoantibodies to thyroglobulin or thyroid microsomes, was rare even in hypothyroid dogs.

The current study was performed on samples from 18 dogs with T₃ AA to characterize these antibodies and measure total T₃ in their presence. The average affinity constant of $2.24 \times 10^{10} M^{-1}$ was in the same range as T₃ antisera produced in rabbits for use in T₃ RIA. The T₄ cross-reactivity was less than 1% in all 18 dogs, and only one sample had T₄ binding greater than normal values.

The low T₄ cross-reactivity brings into question the nature of the antigens that stimulated the production of T₃ AA. The antibodies may have been initially directed at some portion of the T₃ receptor. Then by an anti-idiotypic mechanism as described by Bottazzo (1), antibodies specific to T₃ could result. Indeed, this possibility is supported by a recent study (15) in which purified rat liver nuclear thyroid hormone receptor (THR) was used to raise antibody to THR in mice.

Another possible antigen might be T₃-enriched thyroglobulin. Data in dogs suggested that thyroid hormone secretion involved the uptake and hydrolysis of thyroglobulin molecules containing a higher ratio of T₃/T₄ than the average population of thy-

roglobulin molecules in the colloid (16). However, no specific studies have been performed to address this question.

The fact that T₃ AA was found both in dogs with low total T₄ values and clinical signs of hypothyroidism and in dogs with normal total T₄ values and few symptoms of hypothyroidism may indicate that the latter group represents dogs in the early stages of thyroid gland degeneration. We have not followed the progress in individual dogs with T₃ AA to confirm such speculation.

Euthyroid human patients with T₃ AA generally have elevated total T₃ levels based on ethanol extracted serum, and have T₃ AA with low T₄ cross-reactivity (3-5). Patients with autoantibodies that predominately bind T₄ tend to be hypothyroid (6, 8, 17, 18). A case of "peripheral resistance," however, was reported in a human patient in which a hypothyroid state developed apparently due to the presence of an autoantibody that bound T₃ predominantly. The thyroid gland was normal in terms of [¹³¹I] uptake and biopsy

TABLE VII. CLINICAL SIGNS OF DOGS WITH T₃ AA

	Hypothyroid symptoms*		
	Alopecia	Obesity	Lethargy
Normal T ₄ group			
1	-	+	-
2	-	-	-
3	-	-	-
4	-	-	-
5	-	-	-
6	-	-	-
7	-	-	-
Low T ₄ group			
A	+	+	+
B	-	+	-
C	+	-	-
D	+	-	-
E	+	+	-
F	+	-	-
G	+	+	-
H	+	-	-
I	+	+	+
J	-	+	-
K	+	-	-

* These clinical signs were reported by veterinarians submitting samples to the Endocrine Diagnostic Laboratory.

findings. A rapid increase in autoantibody titer without concurrent elevation in thyroid hormones was thought to have led to hypothyroidism (19).

Results of total T₃ measurement by the modified Sephadex method indicated that T₃ levels in dogs with T₃ AA were elevated in the samples where total T₄ was in the normal range. Total T₃ values were not elevated above the normal range in samples with low total T₄ (Table II). Total T₃ in samples from three rabbits actively immunized against T₃ was more than 100 × higher than in the canine samples. However, considering the higher titer and binding capacity in the rabbit samples, the situation in the canine samples with normal T₄ levels may be analogous, in that free T₃ concentrations in both situations may be in the normal range.

The concentration of T₃ not bound by T₃ AA can theoretically be calculated from the mass action equation when the total T₃, T₃ binding capacity, and T₃ affinity constant are known. That such a calculation is physiologically meaningful was suggested by the fact that in human patients, the free T₃ calculated from the total T₃ and T₃ uptake is highly correlated with free T₃ as measured by equilibrium dialysis (20).

In the dogs with normal T₄ levels, the estimated concentration of T₃ not bound to T₃ AA is in the normal canine range for total T₃. This suggests that a compensatory increase in total T₃ had overcome the binding by T₃ AA resulting in a normal effective total T₃.

It is interesting that total T₃ levels are elevated to a greater extent than total T₄ in animals immunized to T₃ or T₄. Rabbits immunized to T₃ had a 94.0-fold increase in total T₃ and 1.3-fold increase in total T₄; T₄ immunization resulted in a 11.0-fold increase in total T₃ and a 2.1-fold increase in T₄ (7). Similar results were obtained in rats (5). These results indicate a similar thyroid compensatory process may occur in dogs with T₃ AA that have thyroid gland activity capable of maintaining normal total T₄ levels. This suggests that a mechanism was present to maintain a constant free T₃ blood level. In the samples from dogs with T₃ AA in which T₄ concentrations are below normal, esti-

mated levels of available T₃ (T₃ not bound to T₃ AA) are so low that the presence of T₃ AA may have a significant deleterious effect on thyroid status and may cause an exaggeration of clinical hypothyroid symptoms, as well as provide apparently elevated T₃ values in routine total T₃ assays.

1. Bottazzo GC, Doniach D. Autoimmune thyroid disease. *Annu Rev Med* 37:353-359, 1986.
2. Haines DW, Lording PM, Penhale WJ. The detection of canine autoantibodies to thyroid antigens by enzyme-linked immunosorbent assay, hemagglutination and indirect immunofluorescence. *Canad J Comp Med* 48:262-267, 1984.
3. Neeley WE, Alexander NM. Polyclonal 3,5,3'-triiodothyronine (T₃) antibodies in a euthyroid woman and their effect on radioimmunoassay for T₃. *J Clin Endo Metab* 57:851-854, 1983.
4. Blanc MH, Despont JP, Burger AG. Thyroid hormone-binding antibodies. *N Engl J Med* 297(19):1068-1069, 1977.
5. Hehrmann R, Hoffken B, von zur Mühlen A, Creutzig H, Thiele J, Hesch RD. Anti-thyroid hormone autoantibodies under experimental and clinical conditions. *Horm Metab Res* 9:326-332, 1977.
6. Staeheli V, Vallotton MB, Burger A. Detection of human anti-thyroxin and anti-triiodothyronine antibodies in different thyroid conditions. *J Clin Endocrinol Metab* 41:669-675, 1975.
7. Nieschlag E, Herrmann J, Usadel KH, Schwedes U, Schoffling K, Kruskemper HL. Thyroid hypertrophy and hyperfunction caused by active immunization with thyroid hormones. *J Endocrinol* 57:555-556, 1973.
8. Premachandra BN, Walfish PG. Effects and clinical significance of exogenous thyroxine therapy in patients with circulating thyroid hormone autoantibodies. *Amer J Clin Pathol* 78(1):63-68, 1982.
9. Alexander NM, Jennings JF. Radioimmunoassay of serum triiodothyronine on small reusable Sephadex columns. *Clin Chem* 20(10):1353-1361, 1974.
10. Young DW, Sartin JL, Kemppainen RJ. Abnormal canine triiodothyronine-binding factor characterized as a possible triiodothyronine autoantibody. *Amer J Vet Res* 46(6):1346-1350, 1985.
11. Kemppainen RJ, Sartin JL. Evidence for episodic but not circadian activity in plasma concentrations of adrenocorticotropin, cortisol and thyroxine in dogs. *J Endocrinol* 103:219-226, 1984.
12. Scatchard G. The attraction of proteins for small molecules and ions. *Ann NY Acad Sci* 51:660-672, 1949.
13. Belshaw BE. Thyroid Diseases. In: *Textbook of Veterinary Internal Medicine*. Philadelphia, Saunders, Chap 67:pp1604-1607, 1983.

14. Ferguson DC. Thyroid Function Tests in the Dog. *Vet Clin North Amer* **14**(4):783–809, 1984.
 15. Ichikawa K, DeGroot LJ. Antibody against nuclear thyroid hormone receptors. *Biochem Biophys Res Commun* **144**:178–184, 1987.
 16. Laurberg P. Iodothyronine deiodination in the canine thyroid. *Domest Anim Endocrinol* **1**:1–21, 1984.
 17. Herrman J, Rudorff KH, Krovar H, Premachandra BN. Antibody binding of thyroid hormone in juvenile goitrous hypothyroidism. *Horm Metab Res* **9**:394–400, 1977.
 18. Geola FL, Hershman JM, Reed AW, Premachandra BN. Circulating thyroid hormone autoantibodies in a hypothyroid patient: Effect on thyroxin metabolic clearance rate. *J Clin Endocrinol Metab* **53**:580–585, 1981.
 19. Karlsson IA, Wibell L, Wide L. Hypothyroidism due to thyroid hormone-binding antibodies. *N Engl J Med* **296**(20):1146–1148, 1978.
 20. Sawin CT, Choppa D, Albano J, Azizi F. The free triiodothyronine (T₃) index. *Ann Int Med* **88**:474–477, 1978.
-

Received September 17, 1987. P.S.E.B.M. 1988, Vol. 188.

Accepted March 2, 1988.